There’s a new member of MCRA LLC’s C-Suite team.

The company has hired Michael Anselmo as vice president, Reimbursement, Health Economics, and Market Access. As focus on the medical device industry centers more heavily on reimbursement and payers, Anselmo will help clients navigate this evolving landscape.

“Mike is a brilliant addition to our growing team. He has real-world experience identifying the value of new technologies, and he has a substantial track record of winning positive coverage decisions from payers,” said John McDermott, vice president of Reimbursement Strategy and Policy at MCRA. “He looks at the challenge of commercializing new products with the eye of a health economist, which can provide great insight for our clients. We look forward to helping our clients succeed.” 

Anselmo joins MCRA from Amwell, which acquired Silvercloud Health, where he worked as vice president of Healthcare Economics. In this role, Anselmo navigated customer financial requirements to accelerate growth and increase revenue by guiding the implementation of payer strategies. In addition, he has held senior positions in the reimbursement and health economics space for more than a decade at InfoBionic, Abbott Laboratories, and United Health Group. In these roles, Anselmo has worked closely with a variety of payers and providers to contribute to expert guidance and implementation. 

At MCRA, Anselmo will lead the Reimbursement, Healthcare Economics and Market Access team in providing expert consultation and implementation on reimbursement strategies to clients across all medical device therapy specializations. 

“Reimbursement for medical technology has never been more complex and multifaceted. Today’s integrated clinical, regulatory and reimbursement challenges present significant obstacles to the entrepreneurs and companies who look to improve patient care,” MCRA President David Lown said. “With the hiring of Mike, MCRA is taking a leadership position in the medical device industry on getting innovations reimbursed.”

“After the pandemic, there are increasing economic pressures on the global healthcare system and reimbursement is in the forefront of most discussions with healthcare leaders,” Anselmo said. “I am honored to join MCRA at such a critical time in healthcare. Having been at several medical device and technology businesses, I have seen the value added by experienced guidance from industry experts to bring novel products to market. I love the opportunity to help companies bring lifechanging technologies to market to not only impact healthcare finances but also to improve patient quality of life.”

MCRA is a privately held independent medical device, diagnostics and biologics clinical research organization (CRO) and advisory firm. MCRA delivers to its clients industry experience, integrating its six business value creators: regulatory, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics to provide an effort from innovation conception to commercialization. MCRA’s integrated application of these key value-creating initiatives provides value for its clients. MCRA has offices in Washington, D.C.; Hartford, Conn.; New York, N.Y.; and Tokyo; and serves nearly 1,000 clients globally. Its core focus areas of therapeutic experience include orthopedics, spine, biologics, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, anesthesia, general surgery, digital health, neurology, robotics, oncology, general and plastic surgery, urology, and in-vitro diagnostic (IVD) devices and medical device cybersecurity. 
 
Viscogliosi Brothers LLC (VB) founded MCRA in 2004. VB is headquartered in New York City and specializes in funding venture capital, private equity, and merchant banking activities for the neuromusculoskeletal industry.